Boardroom Alpha
S-1/A primary document
BRTX · Amended Registration Statement (Form S-1/A) · Filed February 10, 2026

Biorestorative Therapies IncS-1/A exhibit

ex107.htm

 

EXHIBIT 107

 

Calculation of Filing Fee Tables

 

FORM S-1

(Form Type)

 

BIORESTORATIVE THERAPIES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

333-293322

Table 1: Newly Registered Securities and Carry Forward Securities

 

                                   
   Security
Type
  Security
Class
Title
  Fee
Calculation
or Carry
Forward
Rule
  Amount
Registered
   Proposed
Maximum
Offering
Price Per
Unit
   Proposed
Maximum
Aggregate
Offering
Price(1)(2)
   Fee
Rate
   Amount of
Registration
Fee(3)
 
                              
Fees to Be
Paid
  Equity  Units, consisting of  457(g)        -         -    -    -             - 
   Equity  Common Stock, par value
$0.0001 per share(2)
  457(o)   -    -   $10,000,000.14    0.00013810   $

1,381.00

 
   Equity  Pre-Funded Warrants to purchase shares of Common Stock (4)  457(g)   -    -    -    -    - 
   Equity  Common Stock issuable upon exercise of the Pre-Funded Warrants  457(o)   -    -    Included Above-    0.00013810 -    - 
   Equity  Warrants to purchase shares of Common Stock (4)  457(g)   -    -    -    -    - 
   Equity  Common Stock, par value
$0.0001 per share, issuable upon exercise of Warrants
  457(o)   -    -   $

10,000,000.14

    0.00013810   $

1,381.00

 
   Equity  Placement Agent Warrants (4)  457(g)   -    -    -    -    - 
   Equity  Common Stock, par value $0.0001 per share, issuable upon exercise of Placement Agent Warrants  457(o)   -    -   $

875,000.00

    0.00013810   $120.83 

  Total Offering Amounts        $

20,875,000.14

        $

2,882.83

 
   Total Fees Previously Paid                  $2,858.67 
   Total Fee Offsets                  $0 
   Net Fees Due                  $

24.16

 

 

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the shares of Common Stock being registered hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock being registered hereunder as a result of stock splits, stock dividends or similar transactions.
(2) Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
(3) Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price.
(4) No separate registration fee required pursuant to Rule 457(g) under the Securities Act,

 N/A

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer